Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Midwest Immunology
1380
mi
from 98109
Plymouth, MN
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Midwest Immunology
1380
mi
from 98109
Plymouth, MN
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Midlands Pediatrics PC
1365
mi
from 98109
Papillion, NE
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Midlands Pediatrics PC
1365
mi
from 98109
Papillion, NE
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Winthrop Allergy and Immunology
2417
mi
from 98109
Mineola, NY
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Winthrop Allergy and Immunology
2417
mi
from 98109
Mineola, NY
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Oklahoma Institute of Allergy & Asthma Clinical Research
1523
mi
from 98109
Oklahoma City, OK
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Oklahoma Institute of Allergy & Asthma Clinical Research
1523
mi
from 98109
Oklahoma City, OK
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Allergy and Clinical Immunology Associates
2132
mi
from 98109
Pittsburgh, PA
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Allergy and Clinical Immunology Associates
2132
mi
from 98109
Pittsburgh, PA
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
Allergy, Asthma & Immunology Clinic, P.A.
1666
mi
from 98109
Irving, TX
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
Allergy, Asthma & Immunology Clinic, P.A.
1666
mi
from 98109
Irving, TX
Click here to add this to my saved trials
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated:  1/23/2018
IMMUNOe International Research Centers
1015
mi
from 98109
Thornton, CO
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)
Status: Enrolling
Updated: 1/23/2018
IMMUNOe International Research Centers
1015
mi
from 98109
Thornton, CO
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
UCLA CARE Center CRS (601)
962
mi
from 98109
Los Angeles, CA
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
UCLA CARE Center CRS (601)
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
University of Colorado Hospital CRS (6101)
1029
mi
from 98109
Aurora, CO
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
University of Colorado Hospital CRS (6101)
1029
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Massachusetts General Hospital ACTG CRS (101)
2485
mi
from 98109
Boston, MA
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Massachusetts General Hospital ACTG CRS (101)
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
2161
mi
from 98109
Rochester, NY
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787)
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Unc Aids Crs
2337
mi
from 98109
Chapel Hill, NC
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Unc Aids Crs
2337
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Univ. of Cincinnati CRS (2401)
1967
mi
from 98109
Cincinnati, OH
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Univ. of Cincinnati CRS (2401)
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Case CRS (2501)
2020
mi
from 98109
Cleveland, OH
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Case CRS (2501)
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Vanderbilt Therapeutics CRS (3652)
1971
mi
from 98109
Nashville, TN
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Vanderbilt Therapeutics CRS (3652)
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Houston AIDS Research Team CRS (31473)
1890
mi
from 98109
Houston, TX
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Houston AIDS Research Team CRS (31473)
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Puerto Rico-AIDS CRS (5401)
3726
mi
from 98109
San Juan,
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Puerto Rico-AIDS CRS (5401)
3726
mi
from 98109
San Juan,
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
University of Washington AIDS CRS (1401)
2
mi
from 98109
Seattle, WA
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
University of Washington AIDS CRS (1401)
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated:  1/23/2018
Washington U CRS (2101)
1721
mi
from 98109
Saint Louis, MO
Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)
Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy
Status: Enrolling
Updated: 1/23/2018
Washington U CRS (2101)
1721
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated:  1/23/2018
First Allergy and Clinical Research Center
1032
mi
from 98109
Centennial, CO
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated: 1/23/2018
First Allergy and Clinical Research Center
1032
mi
from 98109
Centennial, CO
Click here to add this to my saved trials
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated:  1/23/2018
Allergy Associates of the Palm Beaches, PA
2687
mi
from 98109
North Palm Beach, FL
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated: 1/23/2018
Allergy Associates of the Palm Beaches, PA
2687
mi
from 98109
North Palm Beach, FL
Click here to add this to my saved trials
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated:  1/23/2018
Pediatrics Allergy/Immunology Association, PA
1680
mi
from 98109
Dallas, TX
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
Phase 1/2 Determination of the Dose of Recominant Human Hyaluronidase (rHuPH20) Required Enabling Up to 600 mg/kg Bodyweight of IGIV, 10% to be Administered Subcutaneously in a Single Infusion Site in Subjects With Primary Immunodeficiency (PID)
Status: Enrolling
Updated: 1/23/2018
Pediatrics Allergy/Immunology Association, PA
1680
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
1030
mi
from 98109
Centennial, CO
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
1030
mi
from 98109
Centennial, CO
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
2687
mi
from 98109
North Palm Beach, FL
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
2687
mi
from 98109
North Palm Beach, FL
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
2178
mi
from 98109
Atlanta, GA
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
2341
mi
from 98109
Durham, NC
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
2020
mi
from 98109
Cleveland, OH
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
2020
mi
from 98109
Cleveland, OH
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
1682
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
1937
mi
from 98109
Galveston, TX
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
1937
mi
from 98109
Galveston, TX
Click here to add this to my saved trials
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  1/23/2018
Clinical Research Facility
1681
mi
from 98109
Milwaukee, WI
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human) 10% (IGIV, 10%) Administered Intravenously or Subcutaneously in Subjects With Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 1/23/2018
Clinical Research Facility
1681
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
UCLA CARE Center CRS (601)
962
mi
from 98109
Los Angeles, CA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
UCLA CARE Center CRS (601)
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Ucsd, Avrc Crs (701)
1065
mi
from 98109
San Diego, CA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Ucsd, Avrc Crs (701)
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Ucsf Aids Crs (801)
680
mi
from 98109
San Francisco, CA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Ucsf Aids Crs (801)
680
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
University of Colorado Hospital CRS (6101)
1029
mi
from 98109
Aurora, CO
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
University of Colorado Hospital CRS (6101)
1029
mi
from 98109
Aurora, CO
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Northwestern University CRS (2701)
1733
mi
from 98109
Chicago, IL
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Northwestern University CRS (2701)
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Rush Univ. Med. Ctr. ACTG CRS (2702)
1733
mi
from 98109
Chicago, IL
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Rush Univ. Med. Ctr. ACTG CRS (2702)
1733
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Brigham and Women's Hosp. ACTG CRS (107)
2485
mi
from 98109
Boston, MA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Brigham and Women's Hosp. ACTG CRS (107)
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Massachusetts General Hospital ACTG CRS (101)
2485
mi
from 98109
Boston, MA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Massachusetts General Hospital ACTG CRS (101)
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Unc Aids Crs
2337
mi
from 98109
Chapel Hill, NC
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Unc Aids Crs
2337
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Moses H. Cone Memorial Hospital CRS (3203)
2297
mi
from 98109
Greensboro, NC
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Moses H. Cone Memorial Hospital CRS (3203)
2297
mi
from 98109
Greensboro, NC
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Univ. of Cincinnati CRS (2401)
1967
mi
from 98109
Cincinnati, OH
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Univ. of Cincinnati CRS (2401)
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
The Ohio State Univ. AIDS CRS (2301)
2008
mi
from 98109
Columbus, OH
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
The Ohio State Univ. AIDS CRS (2301)
2008
mi
from 98109
Columbus, OH
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Vanderbilt Therapeutics CRS (3652)
1971
mi
from 98109
Nashville, TN
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Vanderbilt Therapeutics CRS (3652)
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Houston AIDS Research Team CRS (31473)
1890
mi
from 98109
Houston, TX
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Houston AIDS Research Team CRS (31473)
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
31788 Alabama CRS
2079
mi
from 98109
Birmingham, AL
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
31788 Alabama CRS
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
University of Southern California (1201)
962
mi
from 98109
Los Angeles, CA
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
University of Southern California (1201)
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
University of Colorado Denver ATN CRS (33022)
1020
mi
from 98109
Denver, CO
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
University of Colorado Denver ATN CRS (33022)
1020
mi
from 98109
Denver, CO
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Georgetown University CRS (GU CRS) (1008)
2322
mi
from 98109
Washington,
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Georgetown University CRS (GU CRS) (1008)
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated:  1/24/2018
Children's National Med. Ctr. ATN CRS (33003)
2321
mi
from 98109
Washington,
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status: Enrolling
Updated: 1/24/2018
Children's National Med. Ctr. ATN CRS (33003)
2321
mi
from 98109
Washington,
Click here to add this to my saved trials